邓欢
威尼斯wns.8885556,威尼斯wns.8885556,特设副研究员
教育经历
2004年9月~ 2012年6月: 华中科技大学同济医学院 临床医学八年制
临床医学博士 导师:张虹
工作经历
2023年7月~至今:威尼斯wns.8885556 威尼斯wns.8885556 特设副研究员
2019年9月~ 2023年6月:武汉科技大学 生命科学与健康学院 讲师/硕士生导师
2016年9月~ 2019年9月:华中科技大学同济医学院 博士后/助理研究员
2014年2月~ 2016年8月:德国海德堡癌症研究中心(DKFZ) 博士后
2012年7月~ 2014年1月: 南昌大学第二附属医院 住院医师
科研项目
1. 项目主持人,中央高校自主创新研究基金,2024.02-2025.10, 5万。
2. 项目主持人,威尼斯wns.8885556人才引进科研启动项目,2024.01-2026.12, 15万。
3. 项目主持人,国家自然科学青年基金,ROS响应CRISPRi系统和表观遗传抑制剂共递送纳米粒用于肿瘤PD-L1调控及肿瘤免疫治疗增强,2022.01-2024.12,82102888, 30万。
4. 主要参与人,国家自然科学面上项目,基于单细胞差异网络模型的癌症定向转移标志物挖掘方法研究,2022.01-2025.12,62172312,60万。
代表性研究成果
1. 代表性论著
(1) Juan Wang, Qiyue Chen, Feixia Peng, Shasha Zhao, Cheng Zhang, Xiaoye Song, Deen Yu, Zhongyu Wu, Jiannan Du, Hongwei Ni*, Huan Deng*, Wensheng Deng*. Transcription factor AP-2a activates RNA polymerase III-directed transcription and tumour cell proliferation by controlling expression of c-MYC and p53. Journal of Biological Chemistry. 2023; 299(3): 102945.
(2) Cheng Zhang, Shasha Zhao, Huan Deng*, Shihua Zhang, Juan Wang*, Xiaoye Song, Deen Yu, Yue Zhang, Wensheng Deng*. STAT3 promotes RNA polymerase III-directed transcription by controlling the miR-106a-5p/TP73 axis. Elife. 2023; 12: e82826.
(3) Cheng Zhang, Juan Wang, Xiaoye Song, Deen Yu, Baoqiang Guo, Yaoyu Pang, Shasha Zhao, Huan Deng*, Shihua Zhang*, Wensheng Deng*. STAT3 potentiates RNA polymerase I-directed transcription and tumor growth by activating RPA34 expression. British Journal of Cancer. 2023; 128(5): 766-782.
(4) Zhongyu Wu, Liyun Huang, Shasha Zhao, Juan Wang, Cheng Zhang, Xiaoye Song, Qiyue Chen, Jiannan Du, Deen Yu, Xiaomeng Sun, Yue Zhang, Wensheng Deng*, Shihua Zhang, Huan Deng*. Early growth response 1 strengthens Pol III-directed transcription and transformed cell proliferation by controlling PTEN/AKT signaling activity. International Journal of Molecular Science. 2022; 23: 4930.
(5) Huan Deng#, Songwei Tan#, Xueqin Gao, Chenming Zou, Chenfeng Xu, Kun Tu, Qingle Song, Fengjuan Fan, Wei Huang, Zhiping Zhang*. Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for PD-L1 attenuation and enhanced antitumor immunity. Acta Pharmaceutica Sinica B. 2020; 10(2): 358-373.
(6) Kun Tu#, Huan Deng#, Li Kong, Yi Wang, Ting Yang, Qian Hu, Mei Hu, Conglian Yang, Zhiping Zhang*. Reshaping tumor immune microenvironment through acidity-responsive nanoparticles featured with CRISPR/Cas9-mediated programmed death-ligand 1 attenuation and chemotherapeutics induced immunogenic cell death. ACS Appl Mater Interfaces. 2020; 12(14): 16018-16030.
(7) Wei Huang, Shengyang Jin, Wenbo Yang, Shuo Tian, Chunqing Meng, Huan Deng*, Hong Wang*. Protective effect of Agrimonia pilosa polysaccharides on dexamethasone-treated MC3T3-E1 cells via Wnt/b-Catenin pathway. J Cell Mol Med. 2020; 24(3): 2169-2177.
(8) Huan Deng#, Wei Huang#, Zhiping Zhang*. Nanotechnology based CRISPR-Cas9 system delivery for genome editing: Progress and Prospect. Nano Research. 2019; 12(10): 2437-2450.
(9) Huan Deng, Zhiping Zhang*. The application of nanotechnology in immune checkpoint blockade for cancer treatment. Journal of Controlled Release. 2018; 290: 28-45.